#### **Eosinophilia Associated Lung Diseases**

Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP Thomas H. Davis Chair in Pulmonary Medicine Chief, Section on Pulmonary Critical Care, Allergy & **Immunologic Diseases Wake Forest School of Medicine** 

#### Stephen P. Peters, MD, PhD **Disclosure**

- Basic and Clinical Research
  - NHLBI (AsthmaNet, SARP, SPIROMICS)
  - ALA (ACRC)
- Book Chapters - UpToDate
  - Merck Manuals
- Pharmaceutical Trials
  - Actelion, Amgen, Astra-Zeneca, Boehringer-Ingelheim, Centocor, Cephalon, Genentech, GlaxoSmithKline, Forest, Medimmune, Sanofi-aventis
- Advisory Boards
  - Avisory Boards
    Array Biopharma, AstraZeneca,
    Aerocrine, Airsonett AB, BoehringerIngelheim, Experts in Asthma,
    Gilead, GlausomithKline, Merck,
    Novartis, Ono Pharmaceuticals,
    Pfizer, PPD Development, Quintiles,
    Sunovion, Saatchi & Saatichi,
    Targacept, TEVA, Theron
- Speakers' Bureaus Integrity CE

#### Editorial Boards

- Editorial Boards

  Resp Med, Assoc Editor,
  Resp Research, Assoc Ed

  J Allergy

  Case Reports in Medicine

  US Resp Disease

  J Pulm Resp Medicine

  Clin Exp Med Sciences

  JACI: In Practice

#### **Eosinophilia Associated Lung Diseases: Learning Objectives**

In a Clinical Approach:

- Review Important Eosinophil-Associated **Lung Diseases**
- Discuss the Differential Diagnosis and **Distinguishing Features of These Disorders and Treatment Approaches**

### Eosinophilia and Eosinophilic Lung Disease

- Peripheral Eosinophilia
  - $\ge 400 500$  Eosinophils/ $\mu$ l
- Pulmonary Eosinophilia
  - Tissue Eosinophilia
  - BAL Fluid > 5% (normal <1%)
- Mechanisms
  - cytokine-mediated (mainly IL-5) increased differentiation and survival of eosinophils (extrinsic eosinophilic disorders)
  - Mutation-mediated clonal expansion of eosinophils (intrinsic eosinophilic disorders).

Campos, et al. J Bras Pneumol. 2009; 35:561-573 Simon and Simon. J Allergy Clin Immunol 2007; 119:1291-1300

#### **Case 1 - Presentation**

46 Yr Women Transferred from Central PA Hosp – "Severe Asthma"


- 2 yr cough, wheeze, fatigue
- HBP, depression, migraines
- OCS, (ICS), Salm, Terbut. (PPI, Cipro, Estrogen)
- Hairdresser
- Hunter (Deer, Bear), Fishing
- Exam Cushingoid, Clear Lungs (PEF always low)
- WBC 14K (86P, 1E)
- ABG 7.42/42/70


- Spirometry
  - FEV1/FVC 79% (nl)
  - FEV1 70% pred
  - FVC 72% pred
- TLC 76% pred (Restrict)
- DLCO 50% pred
- CXR, CT chest (nl with min atelectasis)
- ECHO WNL

Methacholine - WNL

**Withdrew Medication** 

Resp Failure - ICU, OLBx





## Eosinophilic Lung Diseases Simon, et al. J Allergy Clin Immunol 2010; 126:3-13 TABLE II. Eosinophilic lung diseases Prevalence of disease Prevalence of disease Asthma Common Mild (up to moderate in SEs and with nasal polyposis) Chronic obstructive pulmonary disease Eosinophilic bronchitis Common (10% of chronic cough) Mild

## **Eosinophilic Lung Diseases: Asthma Key Elements of Asthma**

- Reversible (partial) Airflow Obstruction
- Bronchial Hyperresponsiveness
- Intermittent Symptoms
- PFTs -
  - -No Restriction (NI, Elevated TLC)
  - -Diffusing Capacity (D<sub>L</sub>CO) NI (Elevated)
- Imaging (CXT, CT) Usually Normal

## Sputum Eosinophils in Steroid-Treated vs Steroid-Untreated Subjects with Asthma Not on Steroids (n=350) Steroid Treated (645) Steroid Treated (645) Steroid Treated (645) McGrath, et al. AJRCCM 2012;185:612-619


#### **Characteristics of AECOPD Patients**

Gao, et al. PLoS ONE 8(5): e57678. doi 10.1371

	,		,	
	Eosinophilic > 2.5%	Neutrophilic > 61%	Mixed granulocytic	Paucigranulocytic
N	10	36	5	32
Age (years)	64.8±11.9	65.9±10.5	66.4±11.4	62.8±10.0
BODE score	6(5-6.25)+	5.5(4-7)+	6(4.5-7.5)*	1(0.3-2.8)
GOLD II	0	5	0	7
GOLD III	6	19	1	25
GOLD IV	4	12	4	0
Post-FEV <sub>1</sub> (L)	0.99±0.20 <sup>‡</sup>	1.24±0.52	0.61±0.06 <sup>‡1</sup>	1.34±0.53
Post-FEV <sub>1</sub> /pred (%)	31.4±5.1 <sup>‡</sup>	38.5±9.8 <sup>‡</sup>	22.8±5.0 <sup>‡</sup>	46.7±18.3
FEV <sub>1</sub> /FVC (%)	573±123	59.3±7.0	56.1±5.9	58.7±8.5
12% COPD Patients	General Po	ppulation – Increase	d Blood Eosino	ohils (D Price)

## Obstructive Lung Diseases Differentiating Asthma from COPD

- COPD
  - Emphysema (Decreased D, CO)
  - Chronic Bronchitis (History Cough & Spit)
- Asthma
  - Normal Diffusing Capacity (Could be increased with Exacerbation and Hyperinflation)
  - Chronic Sputum Production Less Common




#### **Case 2 - Recurrent Post-Partum Pulmonary** Eosinophilia

Davies, et al. Thorax 1997; 52:1095-1096

23 year old woman developed idiopathic eosinophilic pneumonia which was successfully treated with corticosteroids. She subsequently developed two

the post-partum period.



#### **Principal Forms of Pulmonary Eosinophilia** (clinical-radiological presentation)

Campos, et al. J Bras Pneumol. 2009; 35:561-573

- 1) Simple pulmonary eosinophilia (Löffler's)
- 2) Chronic eosinophilic pneumonia (CEP)
- 3) Acute eosinophilic pneumonia (AEP)

Not all cases have Peripheral Eosinophilia **Peripheral Infiltrates on Imaging BAL Eosinophilia Characteristic** 

**Differentiating Factors** 

- Chronicity < 30 Days (Loeffler's) + Steroids vs CEP
- Acute Respiratory Failure (AEP)

Eosinophilic Lung Diseases Simon, et al. J Allergy Clin Immunol 2010; 126:3-13		
TABLE II. Eosinophilic lung dis	Prevalence of disease	Degree of peripheral blood eosinophilia*
Fungal airway colonization	Regarded as unusual but probably common in patients with more severe disease	Mild to moderate
Eosinophilic pneumonia (EP)	Unusual	Moderate to severe

## Allergic Bronchopulmonary Aspergillosis (ABPA)

Greenberger. J Allergy Clin Immunol. 2002; 110:685-692

#### **Clinical Features of ABPA**

- Asthma-Like Syndrome
- May Have Sputum ("black plugs")
- Pulmonary Infiltrates (may be "fleeting" and recurring in same areas)
- Airway Obstruction which can Progress to Restriction
- Corticosteroid Responsive

## Allergic Bronchopulmonary Aspergillosis (ABPA)

Greenberger. J Allergy Clin Immunol. 2002; 110:685-692

#### **Diagnosing ABPA**

- Asthma with central bronchiectasis (late and "pathopneumonic") or pulmonary infiltrates
- Total IgE levels greater than 1,000 ng/ml
- Positive skin test reactivity to Aspergillus sp.
- IgE or IgG against Aspergillus sp. in the blood

-	

#### **Case 3 – Presentation**

Wechsler. JAMA 1998; 279:455-457

Healthy Woman, Sinusitis and Asthma at 40 yr

- ICS, theo, β-Ag, frequent OCS
- Zafirlukast Improved over 2 mo; D/C OCS
- 2 wk Rash, Fever, Diarrhea, Dyspnea
- Tachycardia, Wheezes
- Unilateral Foot Drop
- WBC 26K, 37% Eos
- CXR Patchy Infiltrates
- ECHO Global Hypokinesis, EF 35-40%
- Skin Bx lymphocytic and eos perivascular infiltrates
- Lung Bx Necrotizing, granulomatous vasculitis
- Treatment Corticosteroids and Cyclophosphamide

Churg-Strauss: LTRA and Systemic Steroid Discontinuation

#### **Churg-Strauss Syndrome**

Campos, et al. J Bras Pneumol. 2009; 35:561-573

- 1) Allergic phase: presence of asthma or rhinitis
- **2) Eosinophilic phase**: presence of severe persistent peripheral eosinophilia (eosinophil count greater than 1,500 cells/mm<sup>3</sup>) for more than 6 months
- **3) Vasculitic phase:** presence of systemic manifestations and small vessel vasculitis, represented by the involvement of two or more extrapulmonary organs.

However, it is important to remember that the three phases can be dissociated. Asthma is present in 100% of cases.

#### Xolair<sup>R</sup> (Omalizumab) – PI July 2008

#### **Eosinophilic Conditions**

In rare cases, patients with asthma on therapy with Xolair may present with serious systemic eosinophilia sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome a condition which is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between Xolair and these underlying conditions has not been established.

•	
•	

### Principal Forms of Pulmonary Eosinophilia (clinical-radiological presentation)

Campos, et al. J Bras Pneumol. 2009; 35:561-573

- 4) Allergic bronchopulmonary aspergillosis
- 5) Pulmonary eosinophilia associated with a systemic disease:
  - Churg-Strauss syndrome
  - Hypereosinophilic syndrome

#### **Asthma Plus Disorders**

- Churg-Strauss Syndrome Vasculitis, GI involvement, ?Medications
- Allergic Bronchopulmonary Aspergillosis Infiltrates, Obstruction and Restriction, Elevated IgE
- Occupational Asthma (vs RAD –Reactive Airways Dysfunction) – History, PFTs
- Anaphylaxis Multisystem, Serum Tryptase

#### **Eosinophilic Lung Diseases**

Simon, et al. J Allergy Clin Immunol 2010; 126:3-13

Disease	Prevalence of disease	Degree of peripheral blood eosinophilia*
CSS	Rare	Severe
Idiopathic pulmonary fibrosis (IPF)	Unusual	Mild
Lung carcinoma	Common	Mild to severe
Infection with helminthic parasites	Common in countries where parasite infection is endemic	Severe

Ftiol	ngv n	f Du	<b>Imonary</b>	Fosino	nhilia
ELIUI	UKVU	יו Pu	IIIIUIIAI V	EOSIIIC	vviillia

Campos, et al. J Bras Pneumol. 2009; 35:561-573

- 1) Primary or idiopathic
- 2) Secondary
  - a) Known cause
    - Drugs
    - Parasites
    - Toxic products/irradiation
    - Fungal and mycobacterial infection

#### **Drugs Associated with Eosinophilia**

Simon and Simon. J Allergy Clin Immunol 2007; 119:1291-1300

Drug group	Drug examples
Aromatic anticonvulsants	Carbamazepine
	Phenobarbital
	Phenytoin
	Primidone
Nonaromatic anticonvulsants	Lamotrigine
	Valproic acid
	Gabapentin
	Benzodiazepines
Anticancer drugs	Allopurinol
Antimicrobial agents	Minocycline
_	Terbinafine
	Nitrofurantoin
	Isoniazid
	Abacavir
Sulfa drugs	Sulfonamides
_	Dapsone
	Sulfasalazine
Nonsteroidal anti-inflammatory drugs	Oxicam
	Thalidomide
Antihypertensive drugs	Captopril
	Diltiazem
Antidiabetics	Sorbinil

#### **Parasites Causing Eosinophilia**

Phylum	Species
Cestode	Mesocestoides corti*
	Hymenolepis diminuta
Nematode	Angiostrongylus species*
	Anisakis species
	Ascaris lumbricoides
	Ancylostoma species
	Baylisascaris species
	Brugia species*
	Enterobius vermicularis
	Heligmosomoides polygyru
	Litomosoides species*
	Nippostrongylus species*
	Onchocerca species*
	Strongyloides species*
	Toxocara species
	Trichinella species*
	Trichuris species
	Wucheria bancrofti
Trematode	Fasciola species
	Schistosoma species*

#### **Etiology of Pulmonary Eosinophilia**

Campos, et al. J Bras Pneumol. 2009; 35:561-573

#### b) Diseases that can lead to pulmonary eosinophilia

- Diffuse lung diseases: cryptogenic organizing pneumonia; hypersensitivity pneumonia; idiopathic pulmonary fibrosis; Langerhans cell histiocytosis; sarcoidosis.
- Malignant diseases: leukemia; lymphoma; lung cancer; adenocarcinoma involving multiple organs; squamous carcinoma involving multiple organs.
- Connective tissue diseases: rheumatoid arthritis; Sjögren's syndrome.

# Approach to Eosinophilia Simon and Simon. J Allergy Clin Immunol 2007; 119:1291-1300 Eosinophilia Problem inside of eosinophilis Intrinsic eosinophilic disorders Mutaions Pluripotent hematopoietic stem cells - Chronic eosinophilic leukemias - Acute myeloid dustemias - Acute myeloid leukemias - Acute myeloid leukemias - Chronic eosinophilic leukemias - Acute myeloid leukemias - Chronic eosinophilic leukemias - Acute myeloid leukemias - Chronic eosinophilic leukemias - Acute myeloid leukemias - Acute m

#### 

#### **Eosinophilic Lung Diseases**

Simon, et al. J Allergy Clin Immunol 2010; 126:3-13

- Asthma
- COPD
- Eosinophilic Bronchitis
- Drug-Induced
- Fungal Airway Disease
- Eosinophilic Pneumonias
- Chrug-Strauss Syndrome
- Parasitic Lung Diseases
- Diffuse Lung Disseases (e.g. Idiopathic Pulmonary Fibrosis [IPF])
- Carcinoma (e.g. Lung Cancer, Hodgkin's Disease)
- Connective Tissue Disease (RA, Sjögren's)
- Hypereosinophilic Syndrome (HES)
- Stem Cell or Tumor Cell Disorders

## **Eosinophilia Associated Lung Diseases Conclusions**

- Peripheral and/or Lung Eosinophilia is Found in a Number of Common Lung Diseases (asthma COPD) or as Incidental Findings (malignancies, CTDs)
- Initial Steps are Directed Toward R/O Extrinsic Factors (e.g. drugs, parasites)
- Key Differential Factors
  - Presence and Nature of Pulmonary Infiltrates
  - Characteristics of Onset
- Nature of Extra-pulmonary Involvement
- Hematologic Evaluation (bone marrow) Indicated When Diagnosis Unclear
- Treatment Corticosteroids, anti-IL-5 (biologics)

## Eosinophilia Associated Lung Diseases

**Questions?** 

1	1